• <input id="8wm4i"></input>
    <menu id="8wm4i"></menu>
  • <menu id="8wm4i"></menu>
    You are here: Home » Current Affairs ? Coronavirus ? News
    Business Standard

    Coronavirus vaccine update: Mexico gets 1st doses of Chinese vaccine COVAX

    Two coronavirus vaccine frontrunners - Pfizer and Moderna - are set to release late-stage and Phase-II results this month. Catch latest coronavirus vaccine updates here

    Coronavirus | Coronavirus Vaccine | Corona Remedies

    BS Web Team  |  New Delhi 

    Coronavirus, vaccine, covid, drugs, clinical trials

    Covid vaccine update: There are at least 182 vaccine candidates in pre-clinical or clinical-trial stages across the globe. Of these, nine are in final human-trial stage. In India, two vaccines are in Phase-II trials and one (the Oxford University one) in Phase-III. While experts have said vaccines are likely to reach the general public in the March-April 2021, drug makers have been more ambitious with their calculations. Firms like Moderna Inc and Pfizer are eyeing the emergency-use authorisation route to launch their shots by year-end. According to a study, India has used its manufacturing capabilities to pre-order 600 million doses of the Covid-19 vaccine and is negotiating for another billion. The United States, on the other hand, has pre-ordered more doses.

    Covid-19 has infected over 47.2 million people across the globe so far and has claimed nearly 1,210,000 lives. With the virus spreading rapidly and re-surfacing in Europe, every hope is now pinned on vaccine development.

    vaccine progress

    China update

    Mexico has received 1st does of COVAX vaccine from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial on between 10,000 and 15,000 volunteers, foreign minister Marcelo Ebrard said.

    Germany update

    German vaccine maker CureVac has said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers.

    The Phase 1 study has enrolled to date more than 250 healthy individuals aged 18 to 60 years.

    Israel Covid vaccine update: Human trials for underway

    Israel began human trials on November 1 for its Covid-19 vaccine candidate (BriLife) which, if successful, could be ready for use by general public by the end of next summer. "We are in the final stretch," said Shmuel Shapira, Director General of the Israel Institute for Biological Research.

    Oxford coronavirus vaccine update: UK accelerates review of AstraZeneca Covid vaccine

    Britain's Medicines and Healthcare Products Regulatory Agency (MHRA) health regulator has started an accelerated review of its potential coronavirus vaccine.

    In rolling reviews, regulators are able to see clinical data in real time and have dialogue with drug makers on manufacturing processes and trials to accelerate the approval process.

    India Covid-19 vaccine progress: India to get its first vaccine in second quarter of 2021

    Bharat Biotech is planning to launch Covaxin vaccine for coronavirus in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities. The firm's immediate focus is to conduct the Phase 3 trials successfully across sites inthe country. The company's vaccine candidate has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes Covid-19.

    ALSO READ: Bharat Biotech to launch its Covid-19 vaccine in second quarter of 2021

    J&J Covid vaccine status

    Johnson & Johnson plans to start testing its experimental Covid-19 vaccine in youths aged 12 to 18 as soon as possible. "We plan to go into children as soon as we possibly can, but very carefully in terms of safety," J&J's Dr Jerry Sadoff said. Depending on safety and other factors, the company plans to test in even younger children afterwards.

    Moderna coronavirus vaccine update: Moderna prepares global launch of the vaccine

    American biotechnology company Moderna announced that it was preparing for the global launch of its Covid-19 vaccine candidate mRNA-1273. On October 22, the Phase 3 study of mRNA-1273 completed enrollment of 30,000 participants with approximately 37 per cent of participants from diverse communities. The Phase 1 interim analysis of the vaccine, published in The New England Journal of Medicine on July 14, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.

    Russia Covid vaccine status

    Dr Reddy’s Laboratories Ltd has teamed up with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Russia’s Sputnik V Covid-19 vaccine in India. Earlier in October, Dr Reddy's and Russia Direct Investment Fund (RDIF) received nod from DCGI to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

    Pfizer coronavirus vaccine update

    According to a report published in Reuters, the British government expects that a verdict on whether Pfizer Inc-backed Covid-19 vaccine works will be available before the results are in on AstraZeneca Plc's competing vaccine.

    Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas, the report, quoting Times, said.

    Russian coronavirus vaccine (EpiVacCorona)

    Nearly two months after Russia became the first country to approve a Covid-19 vaccine (Sputnik V) amid scepticism from the global scientific community, the country is likely to approve another shot as soon as October 15. Named EpiVacCorona, the vaccine is being developed by Vector State Virology and Biotechnology Center. Russia plans to manufacture an initial 10,000 doses, with production expected to begin in November.

    Dear Reader,

    Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
    We, however, have a request.

    As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

    Support quality journalism and subscribe to Business Standard.

    Digital Editor

    First Published: Mon, November 02 2020. 10:00 IST